Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New targeted immunotherapy compounds designed by Shanghai Birdie Biotech

Feb. 11, 2014

Ganymed Pharmaceuticals begins phase I/II trial of IMAB-027 in advanced ovarian cancer

Feb. 11, 2014

arGEN-X begins phase Ib study of ARGX-111

Feb. 11, 2014

Kyowa Hakko Kirin alters supplemental application for Poteligio in Japan

Feb. 10, 2014

Phase II results show prolonged immune responses with DN24-02 in patients with urothelial cancer

Feb. 10, 2014

TG-01 enters phase IIa trial in operable pancreatic cancer

Feb. 7, 2014

Preliminary phase I results show safety of DC-Ad-GMCAIX treatment in patients with RCC

Feb. 6, 2014

PSMA-ADC treatment leads to CTC and PSA reductions in patients with metastatic CRPC

Feb. 6, 2014

Shionogi initiates phase II study of cancer peptide vaccine in-licensed from OncoTherapy Science

Feb. 6, 2014

XBiotech and EMA agree on phase III registration study for Xilonix

Feb. 3, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...